Premium
IN VIVO AND IN VITRO EFFECTS OF ATRIAL NATRIURETIC PEPTIDE ON RENIN RELEASE
Author(s) -
Ishimitsu Toshihiko,
Hirata Yasunobu,
Matsuoka Hiroaki,
Ishii Masao,
Sugimoto Tsuneaki,
Kangawa Kenji,
Matsuo Hisayuki
Publication year - 1992
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.1992.tb00408.x
Subject(s) - atrial natriuretic peptide , in vivo , in vitro , renin–angiotensin system , medicine , chemistry , peptide , npr1 , npr2 , endocrinology , pharmacology , natriuretic peptide , biochemistry , biology , heart failure , blood pressure , microbiology and biotechnology
SUMMARY 1. This study investigated the effect of atrial natriuretic peptide on renin release from the kidney. The in vitro direct effect was examined in the animal experiment using renal cortical slices of rat, and the in vivo effect was observed in the human infusion study. 2. In the in vitro experiments, α‐human atrial natriuretic peptide (α‐hANP) ranging 10 −9 to 10 −6 mol/L did not change the basal renin release rate from the renal cortical slices (∼9% at 10 −6 mol/L, NS). Isoproterenol (10 −6 mol/L) increased renin release by 40% ( P < 0.001), whereas angiotensin II (10 −6 mol/L) suppressed it by 48% ( P < 0.001). However, α‐hANP did not affect the stimulative effect of isoproterenol or the inhibitory effect of angiotensin II. 3. Also in the human study, infusion of 25 ng/kg per min α ‐hANP failed to change the plasma renin activity in normotensive subjects (–4%) or patients with essential hypertension (+5%), or even in patients with raised renin levels such as renovascular hypertension (+ 10%) or congestive heart failure (‐13%). 4. These results put forth negative views on the direct involvement of atrial natriuretic peptide in renin release from the juxtaglomerular apparatus.